These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 14508145)

  • 1. The role of Ca++-sensitizers for the treatment of heart failure.
    Lehmann A; Boldt J; Kirchner J
    Curr Opin Crit Care; 2003 Oct; 9(5):337-44. PubMed ID: 14508145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan, a new calcium-sensitizing inotrope for heart failure.
    Ng TM
    Pharmacotherapy; 2004 Oct; 24(10):1366-84. PubMed ID: 15628834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan: a novel agent in heart failure.
    Koumallos N; Antoniades C; Tousoulis D; Shirodaria C; Stefanadis C
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):185-91. PubMed ID: 18221085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Levosimendan, a revolution in the world of inotropic agents?].
    Bonnefoy E; Trindade PT
    Rev Med Suisse; 2005 May; 1(21):1425-6, 1428-9. PubMed ID: 15997981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?
    Endoh M
    Br J Pharmacol; 2007 Apr; 150(7):826-8. PubMed ID: 17325657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of Ca2+ sensitizers--update 2001.
    Endoh M
    Cardiovasc Drugs Ther; 2001 Sep; 15(5):397-403. PubMed ID: 11855658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
    Prijić S; Rakić S; Nikolić L; Jovicić B; Stajević M; Vukomanović V; Kosutić J
    Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan: a unique approach to the treatment of heart failure.
    Nawarskas JJ; Anderson JR
    Heart Dis; 2002; 4(4):265-71. PubMed ID: 12147186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan for the treatment of acute heart failure syndromes.
    Parissis JT; Filippatos G; Farmakis D; Adamopoulos S; Paraskevaidis I; Kremastinos D
    Expert Opin Pharmacother; 2005 Dec; 6(15):2741-51. PubMed ID: 16316312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of levosimendan in the treatment of heart failure.
    Kasikcioglu HA; Cam N
    Vasc Health Risk Manag; 2006; 2(4):389-400. PubMed ID: 17323593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites.
    Asif M
    Mini Rev Med Chem; 2018; 18(16):1354-1362. PubMed ID: 27594341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c.
    Sorsa T; Pollesello P; Solaro RJ
    Mol Cell Biochem; 2004 Nov; 266(1-2):87-107. PubMed ID: 15646030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.